"These are fantastic data and suggest CYT387 could be a superior myelofibrosis drug stacked next to Incyte's (INCY_) Jakafi. Unfortunately, relatively few investors believe CYT387's anemia benefit is real. YM Bio's share price has barely budged since interim results from the CYT387 phase II study were presented at the ASH meeting last December.
YM Bio has done nothing to bolster the credibility of CYT387 by dragging its feet on moving the drug into phase III studies. Investor hopes that a Big Pharma partner would come aboard and bless CYT387's potential haven't materialized.
Final phase II data on Sunday that continues to show CYT387 demonstrating robust anemia response and transfusion independence will be welcome news. But unless YM Bio pairs the data with a boffo partner deal, I suspect investors will leave the ASH meeting disappointed."
Seems to be exactly on target. The company had done absolutely nothing to bolster any confidence. They have diluted my shares to a point where I am begging to see 3 again.
If they don't announce a partnership I can guarantee you the investors will not be happy. It has been a YEAR and we have heard NOTHING. They gave themselves GIGANTIC pay raises and the value of my shares has been steadily decreasing.
It's the truth. How long can people hold with NOTHING being done and all we get is but "hey, we're working really hard to move into phase III and possibly partner up, or M & A." Big deal they have $130mm, that will be near gone a year from now. If another dilution is announced I'm scattering like a cockaroach hit by a hot spotlight.
totally agree - AF's comments are right on point. and the management is completely milking the company with their huge pay raises - it could be justified if they had a robust portfolio (they don't - now just one compound), or were managing a complex development program (they are not - in fact, no clarity as to when ph III will start or what the design will be). this has been a joke.